

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>  
12<sup>th</sup> December 2025

Company:	Chordia Therapeutics Inc
Representative:	Chief Executive Officer Hiroshi Miyake (Security Code: 190A TSE Growth Market)
Contact:	IR Manager Ami Kira

**By FISCO Corporation**  
**Notice of Distribution of Our Corporate Research Report**

Kanagawa Japan

12<sup>th</sup> December 2025 –Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) announces that a corporate research report on the Company has been distributed by Fisco Corporation.

For details, please refer to the following link.

[https://www.fisco.co.jp/wordpress/wp-content/uploads/FISCO/chorditherapeutics20251212\\_e.pdf](https://www.fisco.co.jp/wordpress/wp-content/uploads/FISCO/chorditherapeutics20251212_e.pdf)

**About Chordia Therapeutics**

Chordia’s lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including CTX-177, a MALT1 inhibitor, CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website

<https://www.chorditherapeutics.com/en/>.